Abstract
We sought to understand stakeholder perspectives on barriers to metabolic screening for people with severe mental illness. We additionally assessed the feasibility of expanding psychiatrists’ scope of practice to include treatment of cardiometabolic abnormalities. We conducted four focus groups among patients with severe mental illness, community psychiatrists, primary care providers, and public health administrators. Focus group transcripts were thematically analyzed. Three domains emerged: challenges with patient navigation of the complex health care system, problem list prioritization difficulties, and concern that treatment of cardiometabolic abnormalities were beyond the scope of practice of psychiatrists. Stakeholders agreed that navigating the health care system was challenging for this population and led to undertreatment of cardiometabolic risk factors. Expansion of psychiatrists’ scope of practice within community mental health appears acceptable to patients and may be a mechanism to improve cardiometabolic care among people with severe mental illness.
References
Alakeson, V., Frank, R. G., & Katz, R. E. (2010). Specialty care medical homes for people with severe, persistent mental disorders. Health Affairs, 29(5), 867–873. https://doi.org/10.1377/hlthaff.2010.0080.
Amiel, J. M., & Pincus, H. A., Gov’t, U. S., & Review], P. H. S. (2011). The medical home model: new opportunities for psychiatric services in the United States. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t Research Support. Current Opinion in Psychiatry, 24(6), 562–568. https://doi.org/10.1097/YCO.0b013e32834baa97.
Appelbaum, P. S., & Grisso, T. (2001). MacCAT-CR: MacArthur Competence Assessment Tool for Clinical Research.
CDC. (2015). http://www.cdc.gov/nchs/data/ahcd/combined_tables/AMC_2009-2010_combined_web_table01.pdf. Accessed November 30, 2015.
Clark, N. G. (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care, 27(2), 596.
Colton, C. W., Manderscheid, R. W. (2006). Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Preventing Chronic Disease, 3(2), A42.
Compton, M. T., Daumit, G. L., & Druss, B. G. (2006). Cigarette smoking and overweight/obesity among individuals with serious mental illnesses: A preventive perspective. [Review]. Harvard Review of Psychiatry, 14(4), 212–222. https://doi.org/10.1080/10673220600889256.
Daumit, G. L., Goff, D. C., Meyer, J. M., Davis, V. G., Nasrallah, H. A., McEvoy, J. P., et al. (2008). Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. [Comparative Study Randomized Controlled Trial Research Support, N.I.H., Extramural]. Schizophrenia Research, 105(1–3), 175–187. https://doi.org/10.1016/j.schres.2008.07.006.
Davidson, S., Judd, F., Jolley, D., Hocking, B., Thompson, S., & Hyland, B. (2001). Cardiovascular risk factors for people with mental illness. [Research Support, Non-U.S. Gov’t]. The Australian and New Zealand Journal of Psychiatry, 35(2), 196–202.
Druss, B. G. (2007). Improving medical care for persons with serious mental illness: Challenges and solutions. The Journal of Clinical Psychiatry, 68(Suppl 4), 40–44.
Druss, B. G., Marcus, S. C., Campbell, J., Cuffel, B., Harnett, J., Ingoglia, C., et al. (2008). Medical services for clients in community mental health centers: Results from a national survey. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. Psychiatric Services, 59(8), 917–920. https://doi.org/10.1176/appi.ps.59.8.917.
Druss, B. G., & von Esenwein, S. A. (2006). Improving general medical care for persons with mental and addictive disorders: Systematic review. [Research Support, N.I.H., Extramural Review]. General Hospital Psychiatry, 28(2), 145–153. https://doi.org/10.1016/j.genhosppsych.2005.10.006.
Druss, B. G., von Esenwein, S. A., Glick, G. E., Deubler, E., Lally, C., Ward, M. C., et al. (2016). Randomized trial of an integrated behavioral health home: The Health Outcomes Management and Evaluation (HOME) Study. American Journal of Psychiatry, 174(3), 246–255.
Druss, B. G., & Walker, E. R. (2011). Mental disorders and medical comorbidity. The Synthesis Project, 21, 1–26.
Essock, S. M., Covell, N. H., Leckman-Westin, E., Lieberman, J. A., Sederer, L. I., Kealey, E., et al. (2009). Identifying clinically questionable psychotropic prescribing practices for medicaid recipients in New york state. Psychiatric Services, 60(12), 1595–1602. https://doi.org/10.1176/appi.ps.60.12.1595.
Haupt, D. W., Rosenblatt, L. C., Kim, E., Baker, R. A., Whitehead, R., & Newcomer, J. W. (2009). Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. The American Journal of Psychiatry, 166(3), 345–353. https://doi.org/10.1176/appi.ajp.2008.08030383.
Horvitz-Lennon, M., Kilbourne, A. M., & Pincus, H. A. (2006). From silos to bridges: Meeting the general health care needs of adults with severe mental illnesses. Health Affairs, 25(3), 659–669.
Knodel, J. (1993). The design and analysis of focus group studies: A practical approach. In D. A. Morgan (Ed.), Successful focus groups: Advancing the state of the art. Newbury Park, CA: Sage Publications.
Kreuger, R. A. (1998). Analyzing and reporting focus group results. Thousand Oaks, CA: Sage Publications.
Lambert, T. J., & Newcomer, J. W. (2009). Are the cardiometabolic complications of schizophrenia still neglected? Barriers to care. [Review]. The Medical Journal of Australia, 190(4 Suppl), S39–S42.
Lambert, T. J., Velakoulis, D., & Pantelis, C. (2003). Medical comorbidity in schizophrenia. [Research Support, Non-U.S. Gov’t]. The Medical Journal of Australia, 178, S67–S70.
Mangurian, C., Giwa, F., Shumway, M., Fuentes-Afflick, E., Perez-Stable, E. J., Dilley, J. W., et al. (2013). Primary care providers’ views on metabolic monitoring of outpatients taking antipsychotic medication. Psychiatric Services, 64(6), 597–599. https://doi.org/10.1176/appi.ps.002542012.
Mangurian, C., Newcomer, J. W., Vittinghoff, E., Creasman, J. M., Knapp, P., Fuentes-Afflick, E., et al. (2015). Diabetes screening among underserved adults with severe mental illness who take antipsychotic medications. JAMA Internal Medicine. https://doi.org/10.1001/jamainternmed.2015.6098.
McEvoy, J. P., Meyer, J. M., Goff, D. C., Nasrallah, H. A., Davis, S. M., Sullivan, L., et al. (2005). Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. [Comparative Study Research Support, N.I.H., Extramural]. Schizophrenia Research, 80(1), 19–32. https://doi.org/10.1016/j.schres.2005.07.014.
Morgan, D. (1988). Focus groups as qualitative research. Beverly Hills, CA: Sage Publications.
Morrato, E. H., Cuffel, B., Newcomer, J. W., Lombardo, I., Kamat, S., & Barron, J. (2009). Metabolic risk status and second-generation antipsychotic drug selection: a retrospective study of commercially insured patients. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. Journal of Clinical Psychopharmacology, 29(1), 26–32. https://doi.org/10.1097/JCP.0b013e31819294cb.
Morrato, E. H., Druss, B., Hartung, D. M., Valuck, R. J., Allen, R., Campagna, E., et al. (2010). Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs. [Comparative Study Multicenter Study Research Support, Non-U.S. Gov’t]. Archives of General Psychiatry, 67(1), 17–24. https://doi.org/10.1001/archgenpsychiatry.2009.179.
HR2646: Hel** Families in Mental Health Crisis Act (R. T. Murphy, Trans.). (2016) 114th Congress (114 edn.).
Nasrallah, H. A., Meyer, J. M., Goff, D. C., McEvoy, J. P., Davis, S. M., Stroup, T. S., et al. (2006). Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: Data from the CATIE schizophrenia trial sample at baseline. Schizophrenia Research, 86(1–3), 15–22. https://doi.org/10.1016/j.schres.2006.06.026.
Newcomer, J. W. (2005). Second-generation (atypical) antipsychotics and metabolic effects: A comprehensive literature review. CNS Drugs, 19(Suppl 1), 1–93.
Newcomer, J. W., & Hennekens, C. H. (2007). Severe mental illness and risk of cardiovascular disease. [Research Support, N.I.H., Extramural]. JAMA: The Journal of the American Medical Association, 298(15), 1794–1796. https://doi.org/10.1001/jama.298.15.1794.
Olfson, M., Gerhard, T., Huang, C., Crystal, S., & Stroup, T. S. (2015). Premature mortality among adults with schizophrenia in the United States. JAMA Psychiatry. https://doi.org/10.1001/jamapsychiatry.2015.1737.
Palmer, B. W., Dunn, L. B., Appelbaum, P. S., Mudaliar, S., Thal, L., Henry, R., et al. (2005). Assessment of capacity to consent to research among older persons with schizophrenia, Alzheimer disease, or diabetes mellitus: Comparison of a 3-item questionnaire with a comprehensive standardized capacity instrument. [Comparative Study Research Support, N.I.H., Extramural Research Support, U.S. Gov’t, P.H.S.]. Archives of General Psychiatry, 62(7), 726–733. https://doi.org/10.1001/archpsyc.62.7.726.
Parameswaran, S. G., Chang, C., Swenson, A. K., Shumway, M., Olfson, M., & Mangurian, C. V. (2013). Roles in and barriers to metabolic screening for people taking antipsychotic medications: A survey of psychiatrists. Schizophrenia Research, 143(2–3), 395–396. https://doi.org/10.1016/j.schres.2012.08.031.
Reilly, S., Planner, C., Gask, L., Hann, M., Knowles, S., Druss, B., et al. (2013). Collaborative care approaches for people with severe mental illness. Cochrane Database Syst Rev, (11). https://doi.org/10.1002/14651858.CD009531
Rein, A. (2007). Navigating health care: Why it’s so hard and what can be done to make it easier for the average consumer. In R.W.J.F. AcadamyHealth (Ed.), AcademyHealth Issue Brief.
Scharf, D. M., Eberhart, N. K., Schmidt, N., Vaughan, C. A., Dutta, T., Pincus, H. A., et al. (2013). Integrating primary care into community behavioral health settings: Programs and early implementation experiences. Psychiatric Services, 64(7), 660–665.
Scharf, D.M., Eberhart, N.K., Hackbarth, N.S., Horvitz-Lennon, M., Beckman, R., Han, B., Lovejoy, S.L., Pincus, H.A., Burnam, M.A. (2014). Evaluation of the SAMHSA primary and behavioral health care integration (PBHCI) Grant Program: Final Report (Task 13).
SocioCultural Research Consultants LLC. (2015). Dedoose Web application for managing, analyzing, and presenting qualitative and mixed method research data (6.1.18 edn.). Los Angeles, CA.
Steinø, P., Jørgensen, C., & Christoffersen, J. K. (2013). Psychiatric claims to the Danish Patient Insurance Association have low recognition percentages. Danish Medical Journal, 60(8), A4621-A4621.
Stewart, D. W., & Shamdasani, P. N. (1990). Focus groups: Theory and practice. Newbury Park, CA: Sage Publications.
Unutzer, J., Katon, W., Callahan, C. M., Williams, J. W. Jr., Hunkeler, E., Harpole, L., et al. (2002). Collaborative care management of late-life depression in the primary care setting: a randomized controlled trial. JAMA: The Journal of the American Medical Association, 288(22), 2836–2845.
Vanderlip, E. R., Raney, L. E., & Druss, B. G. (2016). A Framework for Extending Psychiatrists’ Roles in Treating General Health Conditions. American Journal of Psychiatry, 173(7), 658–663.
Wang, P. S., Lane, M., Olfson, M., Pincus, H. A., Wells, K. B., & Kessler, R. C. (2005). Twelve-month use of mental health services in the united states: Results from the national comorbidity survey replication. Archives of General Psychiatry, 62(6), 629–640. https://doi.org/10.1001/archpsyc.62.6.629.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Author A was supported by the National Institutes of Mental Health (K23MH093689), the UCSF Hellman Fellows Award for Early-Career Faculty, and the National Center for Research Resources, the National Center for Advancing Translational Sciences, and the Office of the Director, National Institutes of Health, through UCSF-CTSI Grant Number KL2 RR024130. Author E was supported by the National Institutes of Mental Health (K23MH093689), and by the UCSF Public Psychiatry Fellowship at ZSFG. Author G has grant support from Otsuka America Pharmaceutical Inc., consulting fees from Indivior Pharmaceuticals, and he serves on a Data Safety Monitoring Board for Amgen, outside the submitted work. Author I was supported by the NIH Center Grant from the National Institute of Diabetes and Digestive and Kidney Diseases for The Health Delivery Systems-Center for Diabetes Translational Research (CDTR) (P30DK092924) and the NIH/National Institute of Minority Health and Health Disparities (NIMHD) Comprehensive Center of Excellence for Health and Risk in Minority Youth and Young Adults (P60MD006902). The remaining authors declare that they have no conflicts of interest.
Ethical Approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.
Informed Consent
Informed consent was obtained from all individual participants included in the study.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Mangurian, C., Modlin, C., Williams, L. et al. A Doctor is in the House: Stakeholder Focus Groups About Expanded Scope of Practice of Community Psychiatrists. Community Ment Health J 54, 507–513 (2018). https://doi.org/10.1007/s10597-017-0198-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10597-017-0198-4